Targeted Gastrointestinal Delivery of mRNA Lipid Nanoparticles Enables Systemic Vaccination and Glucagon-like Peptide-1 Metabolic Therapy
ACS Nano · 2026
DOI: 10.1021/acsnano.5c18549 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Abdulraouf M Abbas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, Georgia303…. Hauptthemen laut MEDLINE: Nanoparticles, RNA, Messenger, Glucagon-Like Peptide 1, Lipids. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Diabetes Translational Accelerator, National Science Foundation, Georgia Research Alliance.
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) administered parenterally often show poor localization to multiple tissue types, including the pancreas and gastrointestinal (GI) tract. Furthermore, patients typically prefer orally administered drugs to those that are given parenterally. We therefore investigated whether GI LNP administration to buccal, gastric, small intestinal, colonic, and rectal submucosal tissues could simultaneously circumvent parenteral administration while enhancing LNP delivery to previously inaccessible locations. We found that, in addition to local targeting, gastric LNP administration achieved an order of magnitude greater pancreas delivery in rodents than intravenous administration. Gastric dosing of glucagon-like peptide-1 mRNA also improved blood glucose regulation in mice compared with phosphate-buffered saline controls. Additionally, we found that buccal LNP administration targeted local and lymphatic tissues. Furthermore, dosing mice with ovalbumin mRNA resulted in equivalent immunoglobulin G blood titers to those of intramuscular delivery. These results suggest that GI administration can reprogram LNP biodistribution, expanding therapeutic opportunities for both local and systemic nucleic acid delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, Georgia30332, United States.
- Emory Global Diabetes Research Center of the Woodruff Health Sciences Center and Emory University, Atlanta, Georgia30322, United States.
- School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia30332, United States.
- Wearable Intelligent Systems and Healthcare Center, Institute for Matters and Systems, Georgia Institute of Technology, Atlanta, Georgia30332, United States.
- Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia30332, United States.
ORCID-Profile: Bora Jang, Hyejin Kim, Alex Abramson
Förderung
- Diabetes Translational Accelerator
- National Science Foundation
- Georgia Research Alliance
- National Research Foundation of Korea
- Emory University
- NIGMS NIH HHS
- Lakshmi and Subramonian Shankar Fellowship
- Georgia Clinical and Translational Science Alliance
Zitieren
APA
Abbas, A. M., Ghanim, R., Rudden, S., Schultz, D., Jang, B., Shakked, A., Kim, H., Dahlman, J. E., & Abramson, A. (2026). Targeted Gastrointestinal Delivery of mRNA Lipid Nanoparticles Enables Systemic Vaccination and Glucagon-like Peptide-1 Metabolic Therapy. ACS Nano. https://doi.org/10.1021/acsnano.5c18549
Vancouver
Abbas AM, Ghanim R, Rudden S, Schultz D, Jang B, Shakked A, et al. Targeted Gastrointestinal Delivery of mRNA Lipid Nanoparticles Enables Systemic Vaccination and Glucagon-like Peptide-1 Metabolic Therapy. ACS Nano. 2026. doi:10.1021/acsnano.5c18549
BibTeX
@article{Abbas2026,
author = {Abbas, Abdulraouf M and Ghanim, Ramy and Rudden, Sebastian and Schultz, David and Jang, Bora and Shakked, Avraham and Kim, Hyejin and Dahlman, James E and Abramson, Alex},
title = {Targeted Gastrointestinal Delivery of mRNA Lipid Nanoparticles Enables Systemic Vaccination and Glucagon-like Peptide-1 Metabolic Therapy},
journal = {ACS Nano},
year = {2026},
doi = {10.1021/acsnano.5c18549}
}
EUVIMED